

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Guselkumab for treating moderately to severely active ulcerative colitis (ID6237)

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | | |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

One stakeholder highlighted that under the Equality Act 2020, inflammatory bowel disease may be considered a disability because of its impact on daily life.
--

Stakeholders also suggested that the convenience of at home administration may reduce inequalities between people with inflammatory bowel disease and varying degrees of disability.
--

- | | |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|--|

This topic will be evaluated through the cost comparison route for which the populations are similar to previous NICE appraisals.

- | | |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

No.

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No.	

Approved by Associate Director (name): ...Richard Diaz.....
Date: 14 Jan 2025